ripretinib (Qinlock)
Jump to navigation
Jump to search
Indications
- advanced gastrointestinal stromal tumors (GIST) in patients who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
Contraindications
Dosage
Tablets: 50 mg
Pharmacokinetics
- metabolized by CYP3A
- inhibits CYP2C8
- 1/2 life 15 hours
- no increase in QTc
Adverse effects
- > 2%
- increase in serum lipase
- hypophosphatemia
- hypertension
- fatigue
- other
- palmar-plantar erythrodysesthesia syndrome
- new primary skin cancers
- left ventricular systolic dysfunction
- impaired woumd healing
- photosensitivity
- embryo-fetal toxicity
- alopecia, myalgia, nausea/vomiting, abdominal pain, constipation, diarrhea
Mechanism of action
More general terms
References
- ↑ Aakash B Deciphera's Cancer Drug Improves PFS in GI Stromal Tumors. Medscape Aug 13, 2019 https://www.medscape.com/viewarticle/916779
- ↑ Dhillon S. Ripretinib: First Approval. Drugs. 2020 Jul;80(11):1133-1138. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32578014 PMCID: PMC7595980 Free PMC article. Review.
- ↑ Fung S, Shirley M. Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy. Drugs. 2022 Oct;82(15):1541-1548. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36282417 Review.
- ↑ Blay JY, Serrano C, Heinrich MC et al Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 Jul;21(7):923-934. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32511981 PMCID: PMC8383051 Free PMC article. Clinical Trial.